Tag Archives | ADC antibody-drug conjugates

Biotechs Running Again: Rayno Life Science Stocks-See Picks…Updates

Update #1 Amgen Misses on Revs: Enbrel Weighs on Revenues; Profits Top Estimates $3.15 vs $3.00 est Total revenues declined by 1% to $5.5B due to weak Enbrel sales. GAAP EPS increased to $2.79 driven by higher operating margins due to lower costs.Non-GAAP increased 9% to $3.15. Enbrel arthritis and psoriasis sales decreased by 15% […]

Continue Reading 0

Biotech Stocks Sink with Broad Sell-Off on Political Realities…Updates

3/22 Update after close..Relief Rally Awaiting Tomorrow’s Vote Large Caps-mostly green with IBB up 0.54%. Mid Caps-some strength RDUS up 3.48% SGEN up 1.74 %, ,TSRO up 4.08%. Small caps XBI up 0.98%. NASDAQ up 0.48%. ========== Biotech Stocks Sink on Trump Comments Uncertainty Mounts for GOP Healthcare Plan-Fewer Patients Higher Costs? Worse Day of the Year […]

Continue Reading 0

Rayno BioBeat 2017 #2: Biotech Breakthrough Rally

2017 Biotech Breakthrough on a Green Screen Day Biotech stocks got a second wind today and the 2017 rally broke through recent tops that have been strong resistance. Our favorite trading pick the XBI soared 4.82% to $70.48 breaking through the September top and 19% up YTD. The large cap IBB went up 2.89% to […]

Continue Reading 0

Biotech ETFs: Fidelity Biotech Fund Outperforms IBB but XBI is Still the Leader

Fidelity Biotech Portfolio (FBIOX) Is Beginning to Show Benefits of Active Management Biotech stocks have outperformed the market YTD despite a bit of a sell-off recently. During the bubblicious momentum days of 2015 when biotech was on a tear major biotech ETFs outperformed mutual funds. After two severe corrections in 2016 the Fidelity Select Biotechnology […]

Continue Reading 0

Rayno Biopharma Portfolio Update: BLUE FMI IBB…Update-1

Update-1… 2/22/17 Dow closed at a record 20,775.6 with energy the big loser, healthcare down 0.19% and NASDAQ flattish. Biotech stocks sold off with the IBB down 0.85% after hitting $296 near a 52 week high last Thursday. XBI was hit harder down 1.77% to $67.79. Large caps were mainly in the red except ALXN,BIIB […]

Continue Reading 2

Biotech Recap: Rally Continues with Strong Tape…Update-1

Update-1 2/16… Profit Taking Day-Momentum Eases IBB,XBI down ~0.65% Large caps mixed: AMGN,GILD,MRK,RHHBY in green; REGN down 2.86%. Alexion (ALXN) down 1.22% on earnings and guidance. Misses on Revs but up 18.5%. Mid Caps in the red: GWPH down 2%; ICPT down 2.26%, RDUS down 6%.Big  Movers Up on News: Agios (AGIO) up 8%, Esperion (ESPR) […]

Continue Reading 0

Rayno Biobeat 2017 #1: Biotech Rally Driven By M&A

Update-1… 1:45p EST Biotech Rally Biogen (BIIB) looking good in here at $275+, up 4.2% over five days, down 2.7% YTD. IBB and XBI slight gains. ======== Biotech Rally Takes Levels to January Top IBB up 1% to $284.56, up 7.2% YTD XBI up 1.79% to $67.07, up 13.3% YTD, a new high for 2017 […]

Continue Reading 0

2017 J.P.Morgan Healthcare Conference: Large Cap Biotechs Compared to 2016

Large Cap Biopharma Stock Performance YoY from J.P.Morgan Conference The market recovered slightly today from yesterday’s “Trump storm” attacking drug prices. The IBB rose 0.36% and the XBI rose 1.56% . The healthcare sector overall was flat. Selected stocks that continued their upward trend from earlier this week are: Array Biopharma (ARRY) up 7.3%  -Five […]

Continue Reading 0

Biotech Blahs: Out of Favor But Great For Stock Pickers…Update-2

Update-2…1/6/17– Three Day Biotech Rally…12N EST NASDAQ at New Highs 5532 XBI is up 5 points since last Friday’s close to $63.45;The IBB is up 16 points to $280. Investors are betting on a turnaround in healthcare with positive news from the JPMorgan Healthcare Conference next Monday. Despite extremely negative sentiment on the sector, demand for […]

Continue Reading 0

Biotechs Unhinged by Tough Pricing Talk

Biotechs Unhinged-Roiled by Commentary and Tweet storms Biotech stocks rallied briefly early in the week but sold off abruptly over the past two days with a quote from Trump in a Time Person of the Year article as saying, “I’m going to bring down drug prices”. This tough talk is reminiscent of comments by both […]

Continue Reading 0